Global Retinal Vein Occlusion Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Retinal Vein Occlusion Market was valued at $3.9 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 6.2% CAGR, to an estimated market size of $5.2 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The global Retinal Vein Occlusion (RVO) market includes the pharmaceutical therapies, diagnostic imaging, and surgical interventions used to treat blockages in the retinal venous system. The scope covers anti-VEGF injections, corticosteroid implants, and laser photocoagulation for both Central Retinal Vein Occlusion (CRVO) and Branch Retinal Vein Occlusion (BRVO), while excluding general ophthalmic surgeries not related to vascular occlusion.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Retinal Vein Occlusion Market in the period 2025-30:
- The aging global population is a primary driver, as the risk of retinal vascular disorders increases significantly for individuals over the age of 50.
- Rising incidence of comorbidities such as hypertension, diabetes, and atherosclerosis is directly correlating with higher RVO diagnosis rates.
- The market is seeing a rapid shift toward long-acting anti-VEGF formulations and sustained-release implants to reduce the high treatment burden of frequent injections.
- Increased adoption of Optical Coherence Tomography (OCT) and AI-assisted imaging is enabling earlier detection and more precise monitoring of macular edema.
- The entry of biosimilars for blockbuster drugs like Lucentis and Eylea is expected to lower treatment costs and expand patient access in emerging markets.
- Clinical focus is transitioning from volume-based care to personalized treatment regimens, such as "treat-and-extend" protocols, to optimize visual outcomes.
- There is a growing R&D pipeline focused on combination therapies and novel molecules that target both VEGF and Ang-2 pathways for superior efficacy.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Central Retinal Vein Occlusion (CRVO)
- Branch Retinal Vein Occlusion (BRVO)